alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 99.0**

 

**REPORT OF PREDECESSOR AUDITOR (ARTHUR ANDERSEN LLP)**

**ON FINANCIAL STATEMENT SCHEDULE**

 

The following report is a copy of a report previously issued by Arthur Andersen LLP and has not been reissued by Arthur Andersen LLP. This report applies to supplemental Schedule II—Valuation and QualifyingAccounts for the years ended December 31, 2001 and December 31, 2000. 

 

**REPORT OF INDEPENDENT ACCOUNTANTS ON**

**CONSOLIDATED FINANCIAL STATEMENT SCHEDULES**

 

Our audit was made for the purpose of forming an opinion on the basic financial statementstaken as a whole. Schedule II included in Form 10-K is presented for purposes of complying with the Securities and Exchange Commission rules and is not part of the basic financial statements. This schedule has been subjected to the auditingprocedures applied in the audit of the basic financial statements, and in our opinion, fairly states in all material respects the financial data required to be set forth therein in relation to the basic financial statements taken as a whole.
EXHIBIT 32.1


                           CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     In connection with the Quarterly Report on Form 10-Q for the three-month
period ending December 31, 2008 of Lifestyle Choice Meals, Inc., a Nevada
corporation (the "Company"), as filed with the Securities and Exchange
Commission on the date hereof (the "Quarterly Report"), I, Andrea Worsley,
Chairman, President and Chief Financial Officer of the Company certify, pursuant
to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

     1.   The Quarterly Report fully complies with the requirements of Section
          13(a) or15(d) of the Securities and Exchange Act of 1934, as amended;
          and

     2.   The information contained in this Quarterly Report fairly presents, in
          all material respects, the financial condition and results of
          operation of the Company.



/s/ ANDREA WORSLEY
__________________
    Andrea Worsley
    President, Secretary Treasurer, Principal Executive Officer,
    Principal Financial Officer and Director


Date: February 2, 2009
AGENDA 

Advisory Board on Radiation and Worker Health – Meeting 59

Teleconference Meeting 

November 6, 2008 

Teleconference Phone: 866-659-0537 

Participant Code: 9933701 

11:00 a.m. (Eastern Time) Start 

• Roll-call 

• Welcome -- Dr. Ziemer, Board Chair

• Status of Board Recommendation on CANEL SEC Petition -- Mr. Katz 

• Special Exposure Cohort (SEC) Petition Status Updates - Mr. Rutherford

• Updates from Work Groups and Dose Reconstruction Subcommittee –WG/SC Chairs

• Update on Board Technical Support Contractor Activities – Mr. Mauro

- Review of OCAS IG 003 – Mr. Katz

• Update on Selection of the Board’s Contractor – Mr. Katz 

• Board Response to Congressional Letter from Senator Charles Schumer, Senator Hillary 

Clinton, and Representative Louise Slaughter -- Dr. Ziemer 

• New GAO Evaluation & Privacy Act Reminders – Ms. Homoki-Titus, OGC 

• Future Plans – All Board Members

- Update on Implementing IT Security -- Mr. Katz
---

---

Exhibit 13.1

CERTIFICATION PURSUANT
TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report
of Eltek Ltd. (the Company) on Form 20-F for the period ending December 31,
2007 as filed with the Securities and Exchange Commission on the date hereof (the
Report), I, Arieh Reichart, Chief Executive Officer of the Company, certify,
pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley
Act of 2002, that:

(1)       
          The Report fully complies with the requirements of section 13(a) or 15(d) of the
          Securities Exchange Act of 1934; and

(2)       
          The information contained in the Report fairly presents, in all material
          respects, the financial condition and results of operations of the Company.

|/s/ Arieh Reichart *
Arieh ReichartChief Executive Officer
|------------------------------------------------------------------------

April 28, 2008

*     The originally executed copy of
this Certification will be maintained at the Companys offices and will be made
available for inspection upon request.



---

---
Exhibit 4.1


 


THE BANK OF NEW YORK MELLON


NEW YORK’S FIRST BANK-FOUNDED 1784 BY ALEXANDER HAMILTON


 


 


2 HANSON PLACE, 12TH FLOOR, BROOKLYN,
N.Y. 11217


 


 


 


November 24, 2015


 


Hennion & Walsh, Inc.


2001 Route 46, Waterview Plaza


Parsippany, New Jersey 07054


 


Smart Trust, High 20 Dividend Strategy Trust,
Series 12


 


Dear Sirs:


The Bank of New York
Mellon is acting as trustee for Smart Trust, High 20 Dividend Strategy Trust, Series 12 set forth above (the “Trust”).
We enclosed a list of the Securities to be deposited in the Trust on the date hereof. The prices indicated therein reflect our
evaluation of such Securities as of close of business on November 23, 2015, in accordance with the valuation method set forth in
the Standard Terms and Conditions of Trust and Trust Agreement. We consent to the reference to The Bank of New York Mellon as the
party performing the evaluations of the Trust Securities in the Registration Statement (No. 333-206742) filed with the Securities
and Exchange Commission with respect to the registration of the sale of the Trust Units and to the filing of this consent as an
exhibit thereto.


 


 


	 	Very truly yours,
	 	 
	 	/s/ GERARDO CIPRIANO
	 	Gerardo Cipriano
	 	Vice President
IN THE UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF FLORIDA

TALLAHASSEE DIVISION

ASHLEY ANDERSON,

Plaintiff,

v. CASE NO. 4:11-cv-203-RS-WCS

ODELIA TOUCHETTE

and NICKY SHELLEY,

Defendants.

_________________________________/

ORDER

Before me is Defendant Nicky Shelly’s Motion to Strike Dr. Bruce Rodan, 

or in the Alternative to Allow Update Deposition of Dr. Joseph Utz and/or for 

Continuance of the Trial (Doc. 26). Defendant’s Motion to Strike is DENIED

because Dr. Bruce Rodan is a treating physician being used as a rebuttal witness. 

Therefore, the timing requirements of disclosing expert witnesses do not apply to 

him. Roby v. State Farm Mut. Auto. Ins. Co., 2001 WL 36096492, 2* (S.D. Fla. 

Oct. 29, 2001). Defendant’s Motion to Allow Update Deposition of Dr. Joseph 

Utz is GRANTED. The Parties shall update his deposition testimony not later 

than February 6, 2012. Defendant’s Motion to Continue Trial is DENIED.

ORDERED on January 20, 2012.

/S/ Richard Smoak 

RICHARD SMOAK

UNITED STATES DISTRICT JUDGE

Case 4:11-cv-00203-RS-WCS Document 32 Filed 01/20/12 Page 1 of 1
EXHIBIT 32.2




Certification pursuant to 18 U.S.C. 1350,


as adopted pursuant to Section 906 of the Sarbanes-Oxley act of 2002







In connection with the accompanying Form 10-K of ZAP for the year ended December 31, 2009, William Hartman, Chief Financial Officer of ZAP, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:




(1)           such Form 10-K of ZAP for the year ended December 31, 2009, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange of 1934; and




(2)           the information contained in such Form 10-K of ZAP for the year ended December 31, 2009, fairly presents, in all material respects, the financial condition and results of operations of ZAP .


Date:  March 31, 2010
By:
/s/ William HartmanWilliam HartmanChief Financial Officer
Exhibit 109



		

			Exhibit 10.9

		




		
			THE FEMALE HEALTH COMPANY
		

		
			515 North State Street, Suite 2225
		

		
			Chicago, IL 60654
		

		
			 
		

		
			August 27, 2015
		

		
			 
		

		
			Donna Felch
		

		
			N5346 Meadowlark Road
		

		
			Sheboygan Falls, WI 53085
		

		
			 
		

		
			 
		

		
			Dear Donna:
		

		
			 
		

		
			Reference is made to the Consulting Agreement, dated as of January 1, 2013, as amended (the "Agreement"), between you and The Female Health Company (the "Company").  You have agreed, effective July 14, 2015, to accept a special assignment in the capacity of a director of the Company in reference to oversight of Administration and FC2. 
		

		
			 
		

		
			The purpose of this letter agreement is to set forth our agreement regarding the termination of the Agreement effective as of July 14, 2015, now that you have the additional responsibilities pursuant to your special assignment.  In that regard, we agree that the Agreement shall be terminated effective as of July 14, 2015, and neither party shall have any further rights or obligations thereunder.  We also agree that all compensation paid to you under the Agreement for the period between July 14, 2015 and August 27, 2015, shall be deducted from the compensation payable to you for your special assignment for such period.
		

		
			 
		

		
			If you agree to the foregoing, please so indicate by signing where indicated below.
		

		
			 
		

		
			 
		

		
			Yours very truly,
		

		
			 
		

		
			THE FEMALE HEALTH COMPANY
		

		
			 
		

		
			 
		

		
			BY /s/  O.B. Parrish
		

		
			O.B. Parrish, Chief Executive Officer
		

		
			 
		

		
			Agreed to as of the date first above written:
		

		
			 
		

		
			/s/   Donna Felch
		

		
			Donna Felch
**EXHIBIT      32.1**

**CERTIFICATION      OF CHIEF EXECUTIVE OFFICER**

**PURSUANT      TO 18 U.S.C. SECTION 1350, AS ADOPTED**

**PURSUANT      TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

|                                        |                                                                                                                             |                                  |
|---------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
|                                             |                                                                                                                             | /*s*/ *Jacques              Mot* |
|                                        | *Jacques                Mot**President                and Chief Executive Officer**New                Generation Holdings, Inc.* |
|                                        |                                                                                                                             |
| November              30,              2006 |                                                                                                                                  |

----

**EXHIBIT      32.1**

**CERTIFICATION      OF CHIEF FINANCIAL OFFICER**

**PURSUANT      TO 18 U.S.C. SECTION 1350, AS ADOPTED**

**PURSUANT      TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

|   |                                                                                                                          |                                     |
|--------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
|   |                                                                                                                          | /*s*/ *Robert              Scherne* |
|   | *Robert                Scherne**Interim                Chief Financial Officer**New                Generation Holdings, Inc.* |
|   |                                                                                                                          |

----
[Federal Register Volume 72, Number 42 (Monday, March 5, 2007)]
[Notices]
[Pages 9762-9763]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 07-978]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Notice of Meeting

    In accordance with section 10(d) of the Federal Advisory Committee 
Act (5 U.S.C., Appendix 2), announcement is made of a Health Care 
Policy and Research Special Emphasis Panel (SEP) meeting.
    A Special Emphasis Panel is a group of experts in fields related to 
health care research who are invited by the Agency for Healthcare 
Research and Quality (AHRQ), and agree to be available, to conduct on 
an as needed basis, scientific reviews of applications for AHRQ 
support. Individual members of the Panel do not attend regularly-
scheduled meetings and do not serve for fixed terms or a long period of 
time. Rather, they are asked to participate in particular review 
meetings which require their type of expertise.
    Substantial segments of the upcoming SEP meeting listed below will 
be closed to the public in accordance with the Federal Advisory 
Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 
552b(c)(6). Grant applications for ``The Centers for Education and 
Research on Therapeutics (CERTs),'' are to be reviewed and discussed at 
this meeting. These discussions are likely to reveal personal 
information concerning individuals associated with the applications. 
This information is exempt from mandatory disclosure under the above-
cited statutes.

    SEP Meeting on: The Centers for Education and Research on 
Therapeutics (CERTs).
    Date: April 16, 2007 (Open on April 16 from 8 a.m. to 8:15 a.m. 
and closed for the remainder of the meeting).

[[Page 9763]]

    Place: John M. Eisenberg Building, AHRQ Conference Center, 540 
Gaither Road, Rockville, Maryland 20850.
    Contact Person: Anyone wishing to obtain a roster of members, 
agenda or minutes of the non-confidential portions of this meeting 
should contact Mrs. Bonnie Campbell, Committee Management Officer, 
Office of Extramural Research, Education and Priority Populations, 
AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850, 
Telephone (301) 427-1554.
    Agenda items for this meeting are subject to change as 
priorities dictate.

    Dated: February 20, 2007.
Carolyn M. Clancy,
Director.
[FR Doc. 07-978 Filed 3-2-07; 8:45 am]
BILLING CODE 4160-90-M
AGENDA 

Advisory Board on Radiation and Worker Health 

Linde Ceramics Work Group 

2 September 2009 9:30 a.m. 

Cincinnati Airport Marriott 

2395 Progress Dr. 

Hebron, KY 41048 

859-586-0166 

Conference Call Number: 1-866-659-0537. 

Participant Pass Code: 9933701 

Work Group Members:

Genevieve S. Roessler, Chair 

Josie Beach 

Michael Gibson 

James Lockey 

Welcome: Genevieve Roessler, WG Chair 

Preliminaries: Ted Katz 

SEC Petition 107 

NIOSH: Chris Crawford 

 SEC 107 Petition Evaluation Report 

SC&A: Steve Ostrow 

 Review of SEC Petition 107 and NIOSH Petition Evaluation Report 

Antoinette Bonsignore: Petitioner Comments 

WG Discussion/Plans/Recommendations 

Site Profile Review Follow-up 

SC&A: Steve Ostrow 

Assessment of the Disposition of SC&A’s Site Profile Review Issues 

NIOSH: Chris Crawford 

 Site profile status 

WG Discussion/Plans/Recommendations
Exhibit 32

10-K

|   | (1) | To my knowledge, the report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------|

|                    |
|-------------------------|
|                    |
| /s/ John D. Thomas |
| John D. Thomas          |
| Chief Executive Officer |
In the United States Court of Federal Claims

OFFICE OF SPECIAL MASTERS

No. 19-571V 

UNPUBLISHED

JULIE LYONS, 

 Petitioner,

v. 

SECRETARY OF HEALTH AND 

HUMAN SERVICES,

Respondent.

Chief Special Master Corcoran 

Filed: July 7, 2020

Special Processing Unit (SPU); 

Ruling on Entitlement; Concession;

Table Injury; Tetanus Diphtheria 

acellular Pertussis (Tdap) Vaccine;

Shoulder Injury Related to Vaccine 

Administration (SIRVA)

Ronald Craig Homer, Conway, Homer, P.C., Boston, MA, for petitioner.

Mallori Browne Openchowski, U.S. Department of Justice, Washington, DC, for 

respondent.

RULING ON ENTITLEMENT1

On April 17, 2019, Julie Lyons filed a petition for compensation under the 

National Vaccine Injury Compensation Program, 42 U.S.C. §300aa-10, et seq.,

2 (the 

“Vaccine Act”). Petitioner alleges that that she suffered a Shoulder Injury Related to 

Vaccine Administration (“SIRVA”) as a result of her April 18, 2017 Tetanus Diphtheria 

acellular Pertussis (“Tdap”) vaccination. Petition at 1. The case was assigned to the 

Special Processing Unit of the Office of Special Masters.

1 Because this unpublished ruling contains a reasoned explanation for the action in this case, I am 

required to post it on the United States Court of Federal Claims' website in accordance with the EGovernment Act of 2002. 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of 

Electronic Government Services). This means the ruling will be available to anyone with access to 

the internet. In accordance with Vaccine Rule 18(b), Petitioner has 14 days to identify and move to 

redact medical or other information, the disclosure of which would constitute an unwarranted invasion of 

privacy. If, upon review, I agree that the identified material fits within this definition, I will redact such 

material from public access. 

2 National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755. Hereinafter, for 

ease of citation, all “§” references to the Vaccine Act will be to the pertinent subparagraph of 42 U.S.C. § 

300aa (2012).

CORRECTED
2

On July 6, 2020, Respondent filed his Rule 4(c) report in which he concedes that 

Petitioner is entitled to compensation in this case. Respondent’s Rule 4(c) Report at 1. 

Specifically, Respondent indicates that based on his review he has “concluded that 

petitioner suffered a Table SIRVA. No other causes for petitioner’s SIRVA were 

identified.” Id. at 4 citing 42 U.S.C. § 300aa-13(a)(1)(B) (footnote omitted). Respondent 

further agrees that “the statutory six month sequela requirement has been satisfied. § 

300aa-11(c)(D)(I). Therefore, based on the current record, petitioner has satisfied all 

legal prerequisites for compensation under the Act.” Id.

In view of Respondent’s position and the evidence of record, I find that 

Petitioner is entitled to compensation.

IT IS SO ORDERED.

s/Brian H. Corcoran

Brian H. Corcoran

Chief Special Master
[Federal Register Volume 73, Number 24 (Tuesday, February 5, 2008)]
[Notices]
[Page 6733]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-481]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Biomedical Imaging and Bioengineering; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Biomedical Imaging and 
Bioengineering Special Emphasis Panel MRI Imaging.
    Date: March 5, 2008.
    Time: 12 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Two Democracy Plaza, 6707 
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: Ruixia Zhou, PhD, Scientific Review Officer, 
6707 Democracy Boulevard, Democracy Two Building, Suite 957, 
Bethesda, MD 20892, (301) 496-4773, <a href="/cdn-cgi/l/email-protection#f08a989f8582b09d91999cde9e9998de979f86"><span class="__cf_email__" data-cfemail="22584a4d5750624f434b4e0c4c4b4a0c454d54">[email protected]</span></a>.

    Dated: January 29, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-481 Filed 2-4-08; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 32.2




CERTIFICATION PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Quarterly Report of Sagebrush Gold Ltd. n/k/a Pershing Gold Corporation (the “Company”) on Form 10-Q/A for the period ended September 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Adam Wasserman, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:




(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.










Date: March 29, 2012
By:
/s/ Adam WassermanAdam Wasserman

Chief Financial Officer (Principal Financial and Accounting Officer)




A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I,  Andre Benard the Chief Executive Officer and Chief Financial Officer of Calibert Explorations Ltd.. (the Company), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: (i)the Quarterly Report on Form 10-Q of the Company, for the Quarter  ended August 31, 2009, and to which this certification is attached as Exhibit 32 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and(ii)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  By:/s/  Andre BenardName:Andre BenardTitle:Chief Executive Officer and ChiefFinancial OfficerDate:October 15, 2009 A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.